NCT03770039View on ClinicalTrials.gov

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

February 21, 2019

Study Completion Date

February 21, 2019

Conditions
Healthy Male Subjects
Interventions
DRUG

Oral PF-06700841 containing 14C microtracer

Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period

DRUG

Oral unlabeled PF-06700841

60 mg unlabeled PF-06700841 oral dose in 2nd period

DRUG

IV 14C-labeled PF-06700841

30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period

Trial Locations (2)

9728 NZ

PRA Health Sciences, Groningen

3584 BL

PRA Health Sciences Utrecht, Utrecht

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03770039 - Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter